Skip to main content
Figure 1 | BMC Immunology

Figure 1

From: Recombinant human complement component C2 produced in a human cell line restores the classical complement pathway activity in-vitro: an alternative treatment for C2 deficiency diseases

Figure 1

Expression, purification and post-translational modification of rhC2. A) Coomassie stained SDS-PAGE gel of rhC2 at different stages of the purification process. Each lane contains 0.5 μg protein: Lanes: 1. Molecular weight marker, 2. conditioned media, 3. Sepharose pool, 4. purified C2. B) rhC2 glycodigestion with Peptide N-glycosidase (PNGase-F) shows removal of carbohydrates from the protein backbone. Lanes: 1. rhC2 + 1 hour PNGase-F, 2. rhC2 untreated 1 hour, 3. rhC2 + overnight PNGase-F, 4. rhC2 untreated overnight. C) Neuramidase digestion of rhC2 reveals sialic acid removal after digestion of the protein. Lanes: 1. rhC2 + 1 hour Neuramidase, 2. rhC2 untreated.

Back to article page

BMC Immunology

ISSN: 1471-2172

Contact us